News
Novavax expands in Maryland as it gears up for late-stage COVID vaccine trial in the U.S.
Novavax has spent much of 2020 advancing its COVID-19 vaccine candidate through early-stage testing and preparing for manufacturing and distribution. And thanks to the promise of that vaccine and a separate flu program, the company is expanding its Maryland...
News
Mumbai’s Sion Hospital to start phase-3 trials of first indigenous Covid vaccine
The Lokmanya Tilak General Hospital, also known as Sion Hospital, will soon start phase-3 clinical trials of India’s indigenous Covid-19 vaccine—COVAXINTM. As many as 1,000 volunteers between the age of 18 and 60 years will participate in the trial.
Currently,...
News
Aspen Pharmacare, Johnson & Johnson announce deal to produce COVID-19 vaccine candidate
South African pharmaceutical company Aspen Pharmacare on Tuesday announced its deal with the American firm Johnson & Johnson to jointly manufacture its COVID-19 vaccine candidate ‘Ad26.COV3-S’. The manufacture of the vaccine is subject to its approval internationally and in...
News
CureVac COVID-19 vaccine induces immune response in early trial
German vaccine maker CureVac on Monday said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers.
The vaccine candidate was generally well tolerated across all tested doses...
News
Bharat Biotech to launch candidate in Q2 2021, Israel starts human trials
The number of cases of the coronavirus disease (Covid-19) is nearing the 50 million mark across the world and the death toll has risen to more than 1.2 million, according to a worldometers tally, even as the global hunt...
News
Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
Pierre-Alain Ruffieux today joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership...
News
Novartis, Molecular Partners team up to develop DARPin therapeutics for COVID-19
Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read